Krishna Kumar
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$6.3MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $6.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 12, 2025 | NIH | STTR Phase II A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome | $959K | VELUM INC |
| Aug 26, 2025 | NIH | STTR Phase I Peptide YY triagonist weight loss drugs | $315K | VELUM INC |
| May 24, 2024 | NIH | STTR Phase II A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome | $1.1M | VELUM INC |
| May 4, 2023 | NIH | STTR Phase II A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $478K | VELUM INC |
| May 23, 2022 | NIH | STTR Phase II A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $739K | VELUM INC |
| May 1, 2022 | NIH | STTR Phase I Protease Stable N-Terminally Modified Therapeutic Peptides | $367K | VELUM INC with TUFTS UNIVERSITY MEDFORD |
| Apr 29, 2022 | NIH | STTR Phase I Protease Stable N-Terminally Modified Therapeutic Peptides | $367K | VELUM INC |
| Sep 25, 2021 | NIH | STTR Phase I Triagonist Peptide Therapeutics for Neuroprotection | $260K | VELUM INC with TUFTS UNIVERSITY MEDFORD |
| Sep 24, 2021 | NIH | STTR Phase II A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1 | $488K | VELUM INC |
| Sep 23, 2021 | NIH | STTR Phase I Triagonist Peptide Therapeutics for Neuroprotection | $260K | VELUM INC |
| Sep 1, 2019 | NIH | STTR Phase I Rapid High-Fidelity Assembly of Challenging Peptide Sequences | $225K | VELUM INC with TUFTS UNIVERSITY MEDFORD |
| Aug 27, 2019 | NIH | STTR Phase I Rapid High-Fidelity Assembly of Challenging Peptide Sequences | $225K | VELUM INC |
| Aug 7, 2018 | NIH | STTR Phase I Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification | $223K | VELUM INC |
| Aug 7, 2018 | NIH | STTR Phase I Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification | $223K | VELUM INC with TUFTS UNIVERSITY BOSTON |
Peer ranks
Federal funding#171
Awards as PI#57
Patents#273
Companies
- VELUM INCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.